Novo Nordisk expects its GLP-1 drugs Wegovy and Ozempic to soon come off the Food and Drug Administration’s official shortage list, CEO Lars Fruergaard Jørgensen told Barron’s on Wednesday.

Novo Nordisk NOVO.B-2.96%decrease; red down pointing triangle shares rallied Wednesday as investors breathed a sigh of relief after first-quarter earnings beat expectations and the company’s ...

Profit and prosper with the best of expert advice - straight to your e-mail. Novo Nordisk has underperformed the broad market on the price charts over the past 12 months, down 17% vs the S&P 500's ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...

Aliza covers trending news, often focusing on crime and politics. Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities worldwide ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill. Novo Nordisk already makes semaglutide ...

LONDON, April 24 (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NOVOb.CO), opens new tab has raised its annual sales guidance several times a year.

LONDON, Nov 14 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing ...